ReviewScience China. Life sciences2026
An innovative model for integrated traditional Chinese and Western medicine: state-target differentiation and treatment.
Review in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Facing the health challenges posed by global population aging and the increasing burden of chronic non-communicable diseases, Integrated Traditional Chinese and Western Medicine (ITCWM) in China has achieved notable progress over the past 70 years. However, the traditional "combination of disease and syndrome" model exhibits several limitations, including the disconnect between syndrome differentiation and disease stages, insufficient precision in the targeting of Chinese herbal medicines, inconsistencies in disease nomenclature between Traditional Chinese Medicine (TCM) and Western Medicine (WM), and fragmentation in diagnosis and treatment. The "state-target differentiation and treatment" (STDT) model, proposed in 2015, enables the organic integration of TCM's macroscopic state modulation and WM's microscopic targeting. Under the guidance of this theory, Tong Xiaolin classified diabetes into four stages: stagnation, heat, deficiency, and injury. This classification has been incorporated into the International Guideline for Diagnostic and Treatment Principles of Chinese Medicine in Diabetes, issued by the World Federation of Chinese Medicine Societies. By reconstructing the diagnostic and treatment system of ITCWM, reconstructing a modern system for Chinese herbal medicine, and promoting alignment between TCM and WM disease spectra, this approach facilitates the transformation of TCM from experience-based medicine to precision medicine. It also advances the internationalization of TCM and provides a "Chinese solution" for the development of ITCWM and global health governance.
Indexed as
Identifiers
42752780What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.